Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: The benefits of NOACs in patients with atrial fibrillation have been shown in recent studies. New evidence indicates that single rather than dual APT may be adequate when an OAC is used in a patient with a recent coronary stent. Limited evidence suggests a NOAC is preferable to warfarin when additional APT is also required. SUMMARY: The implications of the new findings are to indicate strategies for more effective antithrombotic therapy, while minimizing the risk of major bleeding in patients with ACS and atrial fibrillation. However, additional research studies are required to further optimize treatment strategies in this high-risk population.
|
Authors | David Fitchett, Atul Verma, John Eikelboom, Mina Madan, Eric Cohen, Alan Bell, Paul Dorian |
Journal | Current opinion in cardiology
(Curr Opin Cardiol)
Vol. 29
Issue 1
Pg. 1-9
(Jan 2014)
ISSN: 1531-7080 [Electronic] United States |
PMID | 24284976
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anticoagulants
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
|
Topics |
- Acute Coronary Syndrome
(complications, drug therapy)
- Anticoagulants
(therapeutic use)
- Atrial Fibrillation
(complications, drug therapy)
- Drug Therapy, Combination
- Hemorrhage
(chemically induced)
- Humans
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prosthesis Failure
- Purinergic P2Y Receptor Antagonists
(therapeutic use)
- Stents
- Stroke
(complications, prevention & control)
- Thromboembolism
(complications, prevention & control)
- Treatment Outcome
|